Brind.

Wildon R Farwell joined Satellos Bioscience Inc. as CMO and will advance SAT-3247 in trials.

1 report, 1 independent Updated Jul 16

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Dyn

Keep exploring

The entities involved

Dyn
Internet performance company
- Trump-era tariffs are reportedly benefiting certain AI stocks, coinciding with the spin-off of Millrose Properties, Inc. from Lennar Corporation.Sun 14:13

Coverage

Newest first; wire copies grouped

Jul 16Business WireSatellos Appoints Dr. Wildon Farwell as Chief Medical Officer Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies TORONTO, July 16,